Drug Discovery World

MAY 6, 2024

The transfer of technologies from the lab to the market, is no longer purely via IP out licensing, but rather via start-up M&A deals – start-ups being the de-risking vehicle for large corporates. Biotechs such as ourselves and Owkin are leveraging artificial intelligence.”

Drugs 147

Drugs Science Molecular Biology Clinical Trials 147

The Pharma Data

JANUARY 4, 2021

We believe our allogenic CAR-T platform is significantly stronger with chPD1 target licensed from Longwood University. Chimeric PD-1 T-cells also release cytokines to further initiate immune responses to eradicate the tumor cells. Amorette Barber of Longwood University will be heading up our chPD1 program.

Molecular Biology 40

Molecular Biology Therapies Immune Response Science 40

Drug Target Review

FEBRUARY 28, 2024

Dr Rochlin earned a PhD in Molecular Biology and Genetics from Weill Cornell Medical College, conducting research at Sloan Kettering Institute, and a BA in Biology from the University of Pennsylvania. gammadelta T cells link innate and adaptive immune responses. References Fichtner A, Ravens S, Prinz I.

Therapies 105

Therapies Engineering Molecular Biology Immune Response 105

Codon

FEBRUARY 13, 2024

Phage-based products have been licensed for use as antibacterial agents in the sanitation , food production , and animal health industries. Crucially, it could also make them easier to license as therapeutic agents. There is also a growing body of successful treatments in the U.S., Phage therapies are sold at a pharmacy in Georgia.

Therapies 121

Therapies Virus DNA Clinical Trials 121

Codon

JULY 27, 2023

.” Wellcome Collection , London I wrapped up my series on “30 Days of Great Biology Papers.” ” This was a series of tweets in which I told brief stories behind seminal papers, mostly in molecular biology and biophysics. a lower risk of immune responses. You can read all of them here.

Therapies 52

Therapies RNA DNA Engineering 52

Codon

JULY 27, 2023

.” Wellcome Collection , London I wrapped up my series on “30 Days of Great Biology Papers.” ” This was a series of tweets in which I told brief stories behind seminal papers, mostly in molecular biology and biophysics. a lower risk of immune responses. You can read all of them here.

Therapies 52

Therapies RNA DNA Engineering 52